Literature DB >> 2735203

Long-term course and outcome in unipolar affective and schizoaffective psychoses.

S Opjordsmoen1.   

Abstract

Of 301 first-time admitted patients with delusional psychoses, 50 met DSM-III criteria for major depressive disorder (MDD), 33 schizoaffective disorder, depressive type (SADD), and 94 schizophrenia. At personal follow-up after 3-39 (mean 22) years, the SADD group was recorded in between on course and outcome variables, but closer to MDD. The findings in MDD and SADD were respectively: remission 66% vs. 42%, personality disorders 14% vs. 12%, anxiety disorder or alcohol abuse 2% vs. 6%, psychosis 18% vs. 36% (with bipolar development in 2% vs. 6%, paranoid disorder 2% vs. 3%, schizophrenia 4% vs. 3%). Chronic psychosis was recorded in 10% vs. 27%. No significant outcome difference was found between early onset MDD and SADD cases and those who fell ill at a higher age. The assumption that antidepressants may induce mania could not be confirmed. Normal premorbid personality seemed to predict a favourable course.

Entities:  

Mesh:

Year:  1989        PMID: 2735203     DOI: 10.1111/j.1600-0447.1989.tb10265.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  3 in total

1.  Characteristics and Service Use of Older Adults with Schizoaffective Disorder Versus Older Adults with Schizophrenia and Bipolar Disorder.

Authors:  Stephanie A Rolin; Kelly A Aschbrenner; Karen L Whiteman; Emily Scherer; Stephen J Bartels
Journal:  Am J Geriatr Psychiatry       Date:  2017-04-03       Impact factor: 4.105

2.  Schizoaffective disorder : consistency of diagnosis.

Authors:  A Shrivastava; S Rao
Journal:  Indian J Psychiatry       Date:  1999-10       Impact factor: 1.759

3.  Ten-year outcomes in first episode psychotic major depression patients compared with schizophrenia and bipolar patients.

Authors:  M Heslin; J M Lappin; K Donoghue; B Lomas; U Reininghaus; A Onyejiaka; T Croudace; P B Jones; R M Murray; P Fearon; G A Doody; P Dazzan; T J Craig; C Morgan
Journal:  Schizophr Res       Date:  2016-05-26       Impact factor: 4.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.